172 related articles for article (PubMed ID: 38170228)
21. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).
Zimonjic DB; Popescu NC
Int J Oncol; 2012 Aug; 41(2):393-406. PubMed ID: 22580498
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma.
Jin Y; Lee WY; Toh ST; Tennakoon C; Toh HC; Chow PK; Chung AY; Chong SS; Ooi LL; Sung WK; Lee CG
J Transl Med; 2019 Aug; 17(1):273. PubMed ID: 31429776
[TBL] [Abstract][Full Text] [Related]
23. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma.
Lim HC; Gordan JD
PLoS Comput Biol; 2021 Feb; 17(2):e1008699. PubMed ID: 33561166
[TBL] [Abstract][Full Text] [Related]
24. ADAR2 enzymes: efficient site-specific RNA editors with gene therapy aspirations.
Hajji K; Sedmík J; Cherian A; Amoruso D; Keegan LP; O'Connell MA
RNA; 2022 Oct; 28(10):1281-1297. PubMed ID: 35863867
[TBL] [Abstract][Full Text] [Related]
25. Structure and sequence determinants required for the RNA editing of ADAR2 substrates.
Dawson TR; Sansam CL; Emeson RB
J Biol Chem; 2004 Feb; 279(6):4941-51. PubMed ID: 14660658
[TBL] [Abstract][Full Text] [Related]
26. Functional conservation in human and Drosophila of Metazoan ADAR2 involved in RNA editing: loss of ADAR1 in insects.
Keegan LP; McGurk L; Palavicini JP; Brindle J; Paro S; Li X; Rosenthal JJ; O'Connell MA
Nucleic Acids Res; 2011 Sep; 39(16):7249-62. PubMed ID: 21622951
[TBL] [Abstract][Full Text] [Related]
27. The majority of A-to-I RNA editing is not required for mammalian homeostasis.
Chalk AM; Taylor S; Heraud-Farlow JE; Walkley CR
Genome Biol; 2019 Dec; 20(1):268. PubMed ID: 31815657
[TBL] [Abstract][Full Text] [Related]
28. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
29. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
30. Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes.
Chaudhary K; Poirion OB; Lu L; Huang S; Ching T; Garmire LX
Clin Cancer Res; 2019 Jan; 25(2):463-472. PubMed ID: 30242023
[TBL] [Abstract][Full Text] [Related]
31. ADAR RNA editing in innate immune response phasing, in circadian clocks and in sleep.
Sinigaglia K; Wiatrek D; Khan A; Michalik D; Sambrani N; Sedmík J; Vukić D; O'Connell MA; Keegan LP
Biochim Biophys Acta Gene Regul Mech; 2019 Mar; 1862(3):356-369. PubMed ID: 30391332
[TBL] [Abstract][Full Text] [Related]
32. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).
Zhu Q; Gong L; Wang J; Tu Q; Yao L; Zhang JR; Han XJ; Zhu SJ; Wang SM; Li YH; Zhang W
BMC Cancer; 2016 Oct; 16(1):806. PubMed ID: 27756250
[TBL] [Abstract][Full Text] [Related]
33. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma.
Law PT; Qin H; Ching AK; Lai KP; Co NN; He M; Lung RW; Chan AW; Chan TF; Wong N
J Hepatol; 2013 Jun; 58(6):1165-73. PubMed ID: 23376363
[TBL] [Abstract][Full Text] [Related]
34. SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates.
Shanmugam R; Zhang F; Srinivasan H; Charles Richard JL; Liu KI; Zhang X; Woo CWA; Chua ZHM; Buschdorf JP; Meaney MJ; Tan MH
Nucleic Acids Res; 2018 Aug; 46(14):7379-7395. PubMed ID: 29992293
[TBL] [Abstract][Full Text] [Related]
35. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
36. A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis.
Yoo S; Wang W; Wang Q; Fiel MI; Lee E; Hiotis SP; Zhu J
BMC Med; 2017 Dec; 15(1):214. PubMed ID: 29212479
[TBL] [Abstract][Full Text] [Related]
37. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
[TBL] [Abstract][Full Text] [Related]
38. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatics analysis of the interactions among lncRNA, miRNA and mRNA expression, genetic mutations and epigenetic modifications in hepatocellular carcinoma.
Lin C; Yuan G; Hu Z; Zeng Y; Qiu X; Yu H; He S
Mol Med Rep; 2019 Feb; 19(2):1356-1364. PubMed ID: 30535497
[TBL] [Abstract][Full Text] [Related]
40. Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia.
Schlott T; Ahrens K; Ruschenburg I; Reimer S; Hartmann H; Droese M
Br J Cancer; 1999 Apr; 80(1-2):73-8. PubMed ID: 10389981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
